The US Food and Drug Administration (FDA) approved the use of Abbvie’s Quilipta as a preventive treatment for chronic migraines. This approval gives AbbVie a leg up on Pfizer, whose migraine drug Nurtec ODT is not officially approved for chronic migraines. The decision was made based on data from a phase 3 trial that found the drug significantly reduced migraine day for patients.
According to Zoey Becker, “Trial investigators also sought to determine the proportion of patients who achieved at least a 50% reduction in mean monthly migraine days. In both the U.S.- and EU-focused patient populations, that proportion came out to 41% of patients in the 60-mg group and 42.7% in the 30-mg group, compared with around 26% for placebo.”
To read more, click here.
(Source: Fierce Pharma, April 18th, 2023)
